Esprit BTK Shows Fewer Repeat Interventions Than Balloon Angioplasty

Patients treated with Abbott’s Esprit BTK system had better results and fewer repeat procedures after two years than a control group, the company announced this week. Abbott vascular leader Jennifer Jones-McMeans spoke with Medtech Insight about what the results could mean for patient care.

Abbott's Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit™ BTK System)
• Source: Abbott

More from Medtech Insight

More from Leadership